Woodline Partners LP Allakos Inc. Transaction History

Woodline Partners LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.02 - $3.23 $45,893 - $145,330	44,994 Added 62.88%	116,550 $146,000
Q4 2023 Feb 14, 2024	SELL	$1.72 - $3.18 $244,009 - $451,133	-141,866 Reduced 66.47%	71,556 $195,000
Q3 2023 Nov 14, 2023	BUY	$2.13 - $5.55 $454,588 - $1.18 Million	213,422 New	213,422 $484,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $79.6M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.